The influence of coronary angiography and angioplasty on parameters of hemostasis and fibrinolysis.
The influence of invasive investigations on parameters of hemostasis and fibrinolysis is generally unknown, although this has consequences for the design of prospective studies on the association between those parameters and regression or progression of atherosclerosis. We therefore determined hemostatic and fibrinolytic factors in 12 patients who were admitted to the hospital for coronary angiography (CAG; n = 5) or percutaneous transluminal coronary angioplasty (PTCA; n = 7). Blood samples were drawn under basal circumstances on the day before, the day of and the day after CAG or PTCA. Significant changes occur in the concentrations of platelets and white blood cells, hematocrit (Ht), von Willebrand factor antigen (vWF:ag), antithrombin III-activity (AT III-ag), antithrombin III-antigen (AT III-ant), fibrinogen, plasminogen, alpha2-antiplasmin (alpha2-AP), histidine-rich glycoprotein (HRG), and plasminogen activator inhibitor (PAI)-activity. Mean values of beta-thromboglobulin, platelet factor 4, factor VIII:C, tissue-type plasminogen activator activity (t-PA act) and euglobulin clot lysis time (ECLT) do not differ significantly. After correction for Ht, no significant differences exist between the day before and the day of the procedure; but on the day after CAG and PTCA significant differences occur in white blood cells, factor VIII:C, AT III-ag, alpha2-AP and PAI-act. It is concluded that principally blood samples for investigations on fibrinolysis may be taken on the day before or the day of CAG or PTCA without a loss of quality, if the values are corrected for Ht. Samples taken on the day after the procedure are not useful for such purposes.
Six
A J
AJ
Dept of Cardiology, St Antonius Hospital, Nieuwegein, The Netherlands.
Tjon
R M
RM
Buys
E M
EM
Haas
F
F
Hollander-van Zalk
A
A
Haverkate
F
F
D000787:Angina Pectoris / Q000097:blood* / Q000000981:diagnostic imaging / Q000628:therapy; D000792:Angiography / Q000009:adverse effects; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D000941:Antigens / Q000378:metabolism; D000990:Antithrombin III / Q000378:metabolism; D001772:Blood Cell Count; D001780:Blood Coagulation Tests; D017023:Coronary Angiography; D005169:Factor VIII / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D005342:Fibrinolysis / Q000502:physiology*; D006487:Hemostasis / Q000502:physiology*; D006801:Humans; D008875:Middle Aged; D010958:Plasminogen / Q000378:metabolism; D010978:Platelet Factor 4 / Q000378:metabolism; D011506:Proteins / Q000378:metabolism; D010959:Tissue Plasminogen Activator / Q000378:metabolism; D001620:beta-Thromboglobulin / Q000378:metabolism; D014841:von Willebrand Factor / Q000276:immunology; D000099053:Histidine-Rich Glycoprotein
D000941:Antigens; D011506:Proteins; C029417:Von Willebrand antigen; D001620:beta-Thromboglobulin; D000099053:Histidine-Rich Glycoprotein; D014841:von Willebrand Factor; D010978:Platelet Factor 4; D000990:Antithrombin III; D005169:Factor VIII; D005340:Fibrinogen; D010958:Plasminogen; D010959:Tissue Plasminogen Activator